Novel approaches for vaccine development

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Direct Gene Transfer into Mouse Muscle in Vivo

Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 3×

Toll-like receptor control of the adaptive immune responses

Iwasaki, A., & Medzhitov, R. M. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,166

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 4×

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728

mRNA-based therapeutics--developing a new class of drugs

Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

Shi, T., McAllister, D., O’Brien, K. L., Simões, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acácio, S., Aguayo, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30938-8 · Cited by 2,413

Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein

Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo

Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms

Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034201 · Cited by 1,208

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055

Programming the magnitude and persistence of antibody responses with innate immunity

Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Tang, H., Nakaya, H. I., Ravindran, R., Stewart, S. M., Alam, M. S., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 995

Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them

Leppek, K., Das, R., & Barna, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.103 · Cited by 949

Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines

Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927

In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium

Rosenfeld, M. A., Yoshimura, K., Trapnell, B. C., Yoneyama, K., Rosenthal, E. R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L. E., Stratford-Perricaudet, L. D., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90213-v · Cited by 920

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898

Beyond binding: antibody effector functions in infectious diseases

Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.106 · Cited by 862

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789

Immune Responses to Viral Gene Therapy Vectors

Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788

Regulation of mRNA stability in mammalian cells

Guhaniyogi, J., & Brewer, G. (2001) · Gene · doi:10.1016/s0378-1119(01)00350-x · Cited by 729

Nonviral Gene Delivery: Principle, Limitations, and Recent Progress

Al-Dosari, M. S., & Gao, X. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9143-y · Cited by 706

Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine

Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691

Nonviral delivery of self-amplifying RNA vaccines

Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · cited 1×

Gold Nanoparticles as a Vaccine Platform: Influence of Size and Shape on Immunological Responses in Vitro and in Vivo

Niikura, K., Matsunaga, T., Suzuki, T., Kobayashi, S., Yamaguchi, H., Orba, Y., Kawaguchi, A., Hasegawa, H., Kajino, K., Ninomiya, T., et al. (2013) · ACS Nano · doi:10.1021/nn3057005 · Cited by 652

Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses

Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells

Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625

A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5

McGrory, W. J., Bautista, D., & Graham, F. L. (1988) · Virology · doi:10.1016/0042-6822(88)90302-9 · Cited by 590

mRNA structure regulates protein expression through changes in functional half-life

Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555

Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome

Sharp, F. A., Ruane, D., Claass, B., Creagh, E. M., Harris, J., Malyala, P., Singh, M., O’Hagan, D. T., Pétrilli, V., Tschopp, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804897106 · Cited by 536

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Abbink, P., Larocca, R. A., Barrera, R. A. D. L., Bricault, C. A., Moseley, E. T., Boyd, M. B., Kirilova, M., Li, Z., Ng’ang’a, D., Nanayakkara, O., et al. (2016) · Science · doi:10.1126/science.aah6157 · Cited by 507

Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 490

Biomaterial-assisted targeted modulation of immune cells in cancer treatment

Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 473

Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA

Zhang, Z., Ohto, U., Shibata, T., Krayukhina, E., Taoka, M., Yamauchi, Y., Tanji, H., Isobe, T., Uchiyama, S., Miyake, K., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.011 · Cited by 461

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454 · cited 1×

Simply put: Vaccination saves lives

Orenstein, W. A., & Ahmed, R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704507114 · Cited by 449

Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus

Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E. A., Benhaim, M. A., Ravichandran, R., Carter, L. P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.046 · Cited by 444

In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity

Lynn, G. M., Laga, R., Darrah, P. A., Ishizuka, A. S., Balaci, A. J., Dulcey, A. E., Pechar, M., Pola, R., Gerner, M. Y., Yamamoto, A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3371 · Cited by 441

Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance

Cirelli, K. M., Carnathan, D. G., Nogal, B., Martin, J. T., Rodriguez, O. L., Upadhyay, A. A., Enemuo, C. A., Gebru, E. H., Choe, Y., Viviano, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.012 · Cited by 433

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.006 · Cited by 395

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

Barouch, D. H., O’Brien, K. L., Simmons, N. L., King, S. L., Abbink, P., Maxfield, L. F., Sun, Y.-H., Porte, A. L., Riggs, A. M., Lynch, D. M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2089 · Cited by 384

Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011–20

Ozawa, S., Clark, S. E., Portnoy, A., Grewal, S. K., Brenzel, L., & Walker, D. G. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1086 · Cited by 378

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376

Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein

Sumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., PETER, T. F., Peyerl, F. W., Kishko, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7179 · Cited by 369

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening

Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365

Impact of mRNA chemistry and manufacturing process on innate immune activation

Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354

COVID-19 Vaccine Frontrunners and Their Nanotechnology Design

Chung, Y. H., Beiss, V., Fiering, S., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c07197 · Cited by 354

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Barouch, D. H., Tomaka, F. L., Wegmann, F., Stieh, D. J., Alter, G., Robb, M. L., Michael, N. L., Peter, L. E., Nkolola, J. P., Borducchi, E. N., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31364-3 · Cited by 340

Recent updates on drug resistance in Mycobacterium tuberculosis

Singh, R. K. B., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2019) · Journal of Applied Microbiology · doi:10.1111/jam.14478 · Cited by 340

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Barouch, D. H., Kik, S. V., Weverling, G. J., Dilan, R., King, S. L., Maxfield, L. F., Clark, S., Ng’ang’a, D., Brandariz, K., Abbink, P., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.025 · Cited by 305

Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy

Demento, S. L., Eisenbarth, S. C., Foellmer, H. G., Platt, C., Caplan, M. J., Mark Saltzman, W., Mellman, I., Ledizet, M., Fikrig, E., Flavell, R. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.034 · Cited by 290

Direct Gene Transfer into Nonhuman Primate Myofibers In Vivo

Jiao, S., Williams, P., Berg, R. K., Hodgeman, B. A., Liu, L., Repetto, G. M., & Wolff, J. A. (1992) · Human Gene Therapy · doi:10.1089/hum.1992.3.1-21 · Cited by 283

Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo

Kato, Y., Abbott, R. K., Freeman, B. L., Haupt, S., Gröschel, B., Silva, M., Menis, S., Irvine, D. J., Schief, W. R., & Crotty, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.001 · Cited by 271

A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models

Shan, C., Muruato, A. E., Nunes, B. T. D., Luo, H., Xie, X., Medeiros, D. B. D. A., Wakamiya, M., Tesh, R. B., Barrett, A. D. T., Wang, T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4322 · Cited by 262

The Mechanism of Naked DNA Uptake and Expression

Wolff, J. A., & Budker, V. G. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54001-x · Cited by 260

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 257 · cited 1×

Controlling timing and location in vaccines

Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 255

Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health

Fries, C. N., Curvino, E. J., Chen, J., Permar, S. R., Fouda, G. G., & Collier, J. H. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0739-9 · Cited by 254

Vaccine technologies: From whole organisms to rationally designed protein assemblies

Karch, C. P., & Burkhard, P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.05.001 · Cited by 252

Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines

Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.202 · Cited by 248

Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments

Karlsson, J. E., Vaughan, H. J., & Green, J. J. (2018) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-060817-084055 · Cited by 244

Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity

John, S., Yuzhakov, O., Woods, A., Deterling, J., Hassett, K., Shaw, C. A., & Ciaramella, G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.01.029 · Cited by 229

RNA sensors of the innate immune system and their detection of pathogens

Chen, N., Xia, P., Li, S., Zhang, T., Wang, T. T., & Zhu, J. (2017) · IUBMB Life · doi:10.1002/iub.1625 · Cited by 225

Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

Geisbert, T. W., Bailey, M., Hensley, L. E., Asiedu, C. K., Geisbert, J. B., Stanley, D. A., Honko, A. N., Johnson, J. C., Mulangu, S., Pau, M. G., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02407-10 · Cited by 224

Adenoviral Gene Therapy

Vorburger, S. A., & Hunt, K. K. (2002) · The Oncologist · doi:10.1634/theoncologist.7-1-46 · Cited by 220

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers

Bernstein, D. I., Reap, E. A., Katen, K., Watson, A., Smith, K., Norberg, P., Olmsted, R. A., Hoeper, A., Morris, J., Negri, S., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.135 · Cited by 212

Designing biomaterials with immunomodulatory properties for tissue engineering and regenerative medicine

Andorko, J. I., & Jewell, C. M. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10063 · Cited by 209

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

Probst, J., Weide, B., Scheel, B., Pichler, B. J., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302964 · Cited by 206

Human Clinical Trials of Plasmid DNA Vaccines

Liu, M. A., & Ulmer, J. B. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)55002-8 · Cited by 198

Development and optimization of an adenovirus production process

Kamen, A., & Henry, O. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.503 · Cited by 194

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

Espeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0163-z · Cited by 190

Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids

Bartok, E., & Hartmann, G. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.014 · Cited by 190

Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

Brouwer, P. J. M., Antanasijevic, A., Berndsen, Z. T., Yasmeen, A., Fiala, B., Bijl, T. P. L., Bontjer, I., Bale, J. B., Sheffler, W., Allen, J. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12080-1 · Cited by 185

A review of 65 years of human adenovirus seroprevalence

Mennechet, F. J. D., Paris, O., Ouoba, A. R., Arenas, S. S., Sirima, S. B., Dzomo, G. R. T., Diarra, A., Traore, I. T., Kania, D., Eichholz, K., et al. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1588113 · Cited by 184

Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa

Xiang, Z., Li, Y., Cun, A., Yang, W. P., Ellenberg, S. S., Switzer, W. M., Kalish, M. L., & Ertl, H. C. J. (2006) · Emerging infectious diseases · doi:10.3201/eid1210.060078 · Cited by 178

Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells.

Lemarchand, P., Jaffe, H. A., Danel, C. J., Cid, M. C., Kleinman, H. K., Stratford-Perricaudet, L. D., Perricaudet, M., Pavirani, A., Lecocq, J., & Crystal, R. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6482 · Cited by 176

Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release

Ilyinskii, P. O., Roy, C. J., O’Neil, C. P., Browning, E., Pittet, L. A., Altreuter, D. H., Alexis, F., Tonti, E., Shi, J., Basto, P. A., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.02.027 · Cited by 174

The global burden of HIV and prospects for control

Pandey, A., & Galvani, A. P. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30230-9 · Cited by 173

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2021) · npj Vaccines · doi:10.1038/s41541-021-00311-w · Cited by 165

Differential functional effects of biomaterials on dendritic cell maturation

Park, J., & Babensee, J. E. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.06.006 · Cited by 156

Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens

Maruggi, G., Chiarot, E., Giovani, C., Buccato, S., Bonacci, S., Frigimelica, E., Margarit, I., Geall, A., Bensi, G., & Maione, D. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.11.040 · Cited by 149

Viral Vectors for Gene Transfer

Chen, Y. H., Keiser, M. S., & Davidson, B. L. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.58 · Cited by 146

Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae

Chen, H., Xiang, Z., Li, Y., Kurupati, R. K., Jia, B., Bian, A., Zhou, D., Hutnick, N. A., Yuan, S., Gray, C., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00450-10 · Cited by 145

The influence of innate and pre‐existing immunity on adenovirus therapy

Zaiss, A. K., Machado, H. B., & Herschman, H. R. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22328 · Cited by 144

Shaping humoral immunity to vaccines through antigen-displaying nanoparticles

Irvine, D. J., & Read, B. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.007 · Cited by 141

Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy

Kuai, R., Sun, X., Yuan, W., Ochyl, L. J., Xu, Y., Najafabadi, A. H., Scheetz, L. M., Yu, M., Balwani, I., Schwendeman, A. A., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.041 · Cited by 138

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines

Coughlan, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00909 · Cited by 133

Induction of robust B cell responses after influenza mRNA vaccination Is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells

Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01539 · Cited by 132

Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX

Fields, P. A., Kowalczyk, D. W., Arruda, V. R., Armstrong, E., McCleland, M. L., Hagstrom, J. N., Pasi, J., Ertl, H. C. J., Herzog, R. W., & High, K. A. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0032 · Cited by 129

Preferential Activation of Toll-Like Receptor Nine by CD46-Utilizing Adenoviruses

Iacobelli-Martinez, M., & Nemerow, G. R. (2006) · Journal of Virology · doi:10.1128/jvi.01926-06 · Cited by 113

Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy

Crenshaw, B. J., Jones, L. B., Bell, C. R., Kumar, S., & Matthews, Q. L. (2019) · Biomedicines · doi:10.3390/biomedicines7030061 · Cited by 106

Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors

Andari, J. E., & Grimm, D. (2020) · Biotechnology Journal · doi:10.1002/biot.202000025 · Cited by 105

Catalytic activity of vaccinia mRNA capping enzyme subunits coexpressed in Escherichia coli.

Shuman, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38494-7 · Cited by 102

Innate immune sensing of DNA viruses

Rathinam, V. A. K., & Fitzgerald, K. A. (2011) · Virology · doi:10.1016/j.virol.2011.02.003 · Cited by 102

M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection

Tao, W., & Gill, H. S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.063 · Cited by 99

Polymeric micro- and nanoparticles for immune modulation

Ben‐Akiva, E., Est-Witte, S. E., Meyer, R. A., Rhodes, K. R., & Green, J. J. (2018) · Biomaterials Science · doi:10.1039/c8bm01285g · Cited by 97

Immune Evasion by Adenovirus E3 Proteins: Exploitation of Intracellular Trafficking Pathways

Windheim, M., Hilgendorf, A., & Burgert, H.-G. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-05599-1_2 · Cited by 96

Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses

Chen, N., Johnson, M. M., Collier, M. A., Gallovic, M. D., Bachelder, E. M., & Ainslie, K. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.027 · Cited by 88

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

Baden, L. R., Stieh, D. J., Sarnecki, M., Walsh, S. R., Tomaras, G. D., Kublin, J. G., McElrath, M. J., Alter, G., Ferrari, G., Montefiori, D. C., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30229-0 · Cited by 88

Novel vaccine vectors for HIV-1

Barouch, D. H., & Picker, L. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3360 · Cited by 87

Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles

Pearson, R. M., Podojil, J. R., Shea, L. D., King, N. J. C., Miller, S. D., & Getts, D. R. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.10.001 · Cited by 83

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Tiono, A. B., Nébié, I., Anagnostou, N. A., Coulibaly, A., Bowyer, G., Lam, E., Bougouma, E. C. C., Ouédraogo, A., Yaro, J. B., Barry, A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208328 · Cited by 79

Prevention of Maternal and Congenital Cytomegalovirus Infection

Johnson, J. M., Anderson, B., & Pass, R. F. (2012) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3182510b7b · Cited by 77

Engineering Immune Tolerance with Biomaterials

Gammon, J. M., & Jewell, C. M. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801419 · Cited by 77

Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

Hayton, E., Rose, A., Ibrahimsa, U., Sorbo, M. D., Capone, S., Crook, A., Black, A. P., Dorrell, L., & Hanke, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101591 · Cited by 74

Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity

Northrup, L., Christopher, M. A., Sullivan, B. P., & Berkland, C. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.020 · Cited by 73

New concepts in HIV-1 vaccine development

Stephenson, K. E., D’Couto, H. T., & Barouch, D. H. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.011 · Cited by 73

TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25

Thompson, E. A., Ols, S., Miura, K., Rausch, K. M., Narum, D. L., Spångberg, M., Juraska, M., Wille-Reece, U., Weiner, A. J., Howard, R. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120692 · Cited by 73

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial

Tapia, M. D., Sow, S. O., Ndiaye, B., Mbaye, K. D., Thiongane, A., N'Dour, C. T., Mboup, S., Ake, J. A., Keshinro, B., Akintunde, A., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30016-5 · Cited by 72

Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant

Champion, C. R. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020962050 · Cited by 65

Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine

Matsuda, K., Huang, J., Zhou, T., Sheng, Z., Kang, B. H., Ishida, E., Griesman, T., Stuccio, S., Bolkhovitinov, L., Wohlbold, T. J., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau2710 · Cited by 63

Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world

Leke, R. G. F., King, A. S., Pallansch, M. A., Tangermann, R. H., Mkanda, P., Chunsuttiwat, S., Jack, A., KABORE, B., Kane, I., Khomo, N. E., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30382-x · Cited by 63

Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal

Rodrigues, F. M. P., Marlow, R. D., Simões, M. J., Danon, L., Ladhani, S. N., & Finn, A. H. R. (2020) · JAMA · doi:10.1001/jama.2020.20449 · Cited by 63

Viral vectors as vaccine carriers

Ertl, H. C. J. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.06.001 · Cited by 62

Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions

Baker, A. T., Greenshields‐Watson, A., Coughlan, L., Davies, J. A., Uusi-Kerttula, H. K., Cole, D. K., Rizkallah, P. J., & Parker, A. L. (2019) · Nature Communications · doi:10.1038/s41467-019-08599-y · Cited by 62

Engineering self-assembled materials to study and direct immune function

Tostanoski, L. H., & Jewell, C. M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.005 · Cited by 60

Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System

Artusi, S., Miyagawa, Y., Goins, W. F., Cohen, J. B., & Glorioso, J. C. (2018) · Diseases · doi:10.3390/diseases6030074 · Cited by 60

The old and the new: Prospects for non-integrating lentiviral vector technology

Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58

A Chimpanzee-Origin Adenovirus Vector Expressing the Rabies Virus Glycoprotein as an Oral Vaccine against Inhalation Infection with Rabies Virus

Zhou, D., Cun, A., Li, Y., Xiang, Z., & Ertl, H. C. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.027 · Cited by 57

Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens

Fan, Y., & Moon, J. J. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1403 · Cited by 46

Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases

Yenkoidiok-Douti, L., & Jewell, C. M. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01255 · Cited by 42

Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate T Cell Inhibitory Functions and Are Transiently Increased after Vaccination

Lin, A., Liang, F., Thompson, E. A., Vono, M., Ols, S., Lindgren, G., Hassett, K. J., Salter, H., Ciaramella, G., & Loré, K. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701005 · Cited by 41

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

Goldstein, N. H., Bockstal, V., Bart, S., Lühn, K., Robinson, C., Gaddah, A., Callendret, B., & Douoguih, M. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa586 · Cited by 40

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection

Hartnell, F., Brown, A., Capone, S., Kopycinski, J. T., Bliss, C. M., Makvandi‐Nejad, S., Swadling, L., Ghaffari, E., Cicconi, P., Sorbo, M. D., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03175 · Cited by 36

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors

Abbink, P., Kirilova, M., Boyd, M. B., Mercado, N. B., Li, Z., Nityanandam, R., Nanayakkara, O., Peterson, R., Larocca, R. A., Aïd, M., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01924-17 · Cited by 34

Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR−/− Mice

Larocca, R. A., Mendes, É. A., Abbink, P., Peterson, R., Martinot, A. J., Iampietro, M. J., Kang, Z. H., Aïd, M., Kirilova, M., Jacob-Dolan, C., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.10.001 · Cited by 31

Noncanonical Functions of Antibodies

Dimitrov, J. D., & Lacroix‐Desmazes, S. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.006 · Cited by 30

Taxonomy proposal for Old World monkey adenoviruses: characterisation of several non-human, non-ape primate adenovirus lineages

Pantó, L., Podgorski, I. I., Jánoska, M., Márkó, O., & Balázs Harrach, B. (2015) · Archives of Virology · doi:10.1007/s00705-015-2575-z · Cited by 28

Characterization of a Species E Adenovirus Vector as a Zika virus vaccine

Bullard, B. L., Corder, B. N., Gordon, D. N., Pierson, T. C., & Weaver, E. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-60238-5 · Cited by 24

Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia

Singh, G., Song, S.-J., Choi, E. J., Lee, P. B., & Nahm, F. S. (2020) · The Korean journal of pain · doi:10.3344/kjp.2020.33.3.201 · Cited by 24

Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes

Conrad, S. J., & Liu, J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9065-8_11 · Cited by 22

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22)

Stephenson, K. E., Wegmann, F., Tomaka, F. L., Walsh, S. R., Tan, C. S., Lavreys, L., Ansel, J. L., Kanjilal, D. G., Jaegle, K., Nkolola, J. P., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30001-1 · Cited by 22

Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON®-TB Gold (+) Kenyan adults without evidence of tuberculosis

Walsh, D. S., Owira, V., Polhemus, M. E., Otieno, L., Andagalu, B. M., Ogutu, B. R., Waitumbi, J. N., Hawkridge, A., Shepherd, B. M., Pau, M. G., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.069 · Cited by 16

Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda

Kitonsa, J., Ggayi, A.-B., Anywaine, Z., Kisaakye, E., Nsangi, L., Basajja, V., Nyantaro, M., Watson‐Jones, D., Shukarev, G., Ilsbroux, I., et al. (2020) · Global Health Action · doi:10.1080/16549716.2020.1829829 · Cited by 13

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors

Iampietro, M. J., Larocca, R. A., Provine, N. M., Abbink, P., Kang, Z. H., Bricault, C. A., & Barouch, D. H. (2018) · Journal of Virology · doi:10.1128/jvi.00159-18 · Cited by 10

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076

Neoantigens: promising targets for cancer therapy

Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020

Recent advances in regenerative biomaterials

Cao, D., & Ding, J. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac098 · Cited by 277

Nanoparticle-Based Delivery Systems for Vaccines

Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. K. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 276

Lipid nanoparticles in the development of mRNA vaccines for COVID-19

Wilson, B., & Geetha, K. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103553 · Cited by 265

A Review on Novel Approaches in Vaccine Development

Shaikh Mujeeb Ur Rahman, A. Q. Q. *. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.15779378

Emerging Concepts and Technologies in Vaccine Development

Brisse, M. E., Vrba, S. M., Kirk, N. M., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 329

Advances in Vaccine Development: A Comprehensive Review of Technological Progress and Challenges

Yan, N. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/61/20241449

Vaccine development: Current trends and technologies

Poria, R., Kala, D., Nagraik, R., Walia, Y., Dhir, S., Singh, B., Kaushik, N. K., Noorani, M. S., Kaushal, A., & Gupta, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122331 · Cited by 90

CURRENT PERSPECTIVES IN VACCINE DEVELOPMENT: A COMPREHENSIVE REVIEW

Nikam, D., Kulkarni, S., Yadav, V., & Pawar, A. (2026) · Iterative International Publishers eBooks · doi:10.58532/nbennurfmpiv6b1c23